Commercialization of Organoids

Deepak Choudhury; Aswathi Ashok; May Win Naing

doi:10.1016/j.molmed.2019.12.002

Commercialization of Organoids

Trends Mol Med. 2020 Mar;26(3):245-249. doi: 10.1016/j.molmed.2019.12.002. Epub 2020 Jan 22.

Authors

Deepak Choudhury¹, Aswathi Ashok², May Win Naing²

Affiliations

¹ Bio-Manufacturing Group, Singapore Institute of Manufacturing Technology (SIMTech), Agency for Science, Technology, and Research (A*STAR), 2 Fusionopolis Way, #08-04, Innovis, Singapore. Electronic address: deepakc@SIMTech.a-star.edu.sg.
² Bio-Manufacturing Group, Singapore Institute of Manufacturing Technology (SIMTech), Agency for Science, Technology, and Research (A*STAR), 2 Fusionopolis Way, #08-04, Innovis, Singapore.

PMID: 31982341
DOI: 10.1016/j.molmed.2019.12.002

Abstract

Organoids have been successfully exploited for drug screening, disease modeling, pathogenesis, and regenerative medicine. Herein, we discuss the progress achieved in the commercialization of organoids in the last few years. We further elaborate on the concept of organoid biobank and highlight ethical and regulatory issues surrounding organoid research and commercialization.

Keywords: commercialization; in vitro models; organoids; stem cells; tissue engineering.

MeSH terms

Animals
Biological Specimen Banks
Drug Evaluation, Preclinical / methods*
Humans
Organoids / cytology*
Organoids / drug effects
Precision Medicine / methods
Regenerative Medicine / methods
Tissue Engineering / methods